Pfizer has entered into a strategic funding agreement with Blackstone Life Sciences, securing up to US$1.5 billion to support the clinical development of berobenatide, an investigational monthly GLP-1 receptor agonist being studied for chronic weight management and obesity-related conditions. Under the agreement, Blackstone-managed funds will cover eligible development costs through 2028.
Berobenatide, also known as PF’3944, is being investigated as a potential first-in-class monthly GLP-1 receptor agonist peptide. Pfizer is evaluating its potential as a treatment for obesity and related health conditions, including knee osteoarthritis and obstructive sleep apnea.
As part of its development strategy, Pfizer plans to advance more than 20 clinical trials for obesity and associated conditions in 2026, including 10 ongoing and planned Phase 3 trials for berobenatide. The programme will explore the drug as a standalone treatment and in combination with other nutrient-stimulated hormone (NuSH) peptides, including amylin analogues.
Click here to join our WhatsApp channel here
“Our aim is to bring important new medicines to patients while taking a disciplined approach that pairs internal research investments with targeted investment from capital partners. Today’s announcement helps us advance our comprehensive obesity program and maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas.” said, Cecile Guegan, Chief Financial Officer and Executive Vice President, Pfizer
“We are pleased to further expand our relationship with Pfizer and support the broad and rigorous development of berobenatide as the anchor of Pfizer’s cardiometabolic pipeline. This collaboration is a good example of our leadership in providing capital solutions at scale to advance important medicines and technologies to patients.” said, Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences
The collaboration is expected to support Pfizer’s expanding cardiometabolic pipeline while providing financial flexibility to advance its broader research and development programmes. The agreement also strengthens the partnership between the pharmaceutical company and Blackstone Life Sciences in advancing potential new treatment options for obesity.
Also read: UAE Records 5,122 Suspected Adverse Drug Reaction Reports in 2026
